导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.85% | 3508/4773 |
| 近一周 | - | 406/5458 |
| 近一月 | 3.66% | 217/5421 |
| 近一季 | 3.32% | 420/5205 |
| 近半年 | 0.07% | 1346/4920 |
| 近一年 | -5.28% | 3174/4361 |
| 近两年 | 34.19% | 2152/2954 |
| 近三年 | 25.15% | 1282/2253 |
| 成立以来 | 91.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.11% 4349/4961 |
-4.55% 3517/5312 |
- - |
- - |
| 2025 | 10.16% 2827/4813 |
-1.72% 2761/3635 |
8.64% 322/4076 |
-0.59% 3930/4524 |
3.77% 625/4813 |
| 2024 | 33.80% 65/3463 |
2.99% 640/2808 |
0.97% 518/3014 |
26.96% 239/3129 |
1.35% 1078/3463 |
| 2023 | -5.74% 771/2656 |
-1.27% 1859/2280 |
-0.14% 363/2385 |
4.93% 112/2515 |
-8.89% 2313/2655 |
| 2022 | -12.87% 304/2207 |
-5.45% 192/1919 |
-1.49% 1729/2016 |
-10.97% 477/2113 |
5.07% 490/2208 |
| 2021 | -10.02% 1089/1822 |
-1.94% 555/1255 |
-3.52% 1247/1330 |
-5.28% 790/1466 |
0.42% 1116/1822 |
| 2020 | 2.09% 927/1250 |
-15.59% 983/1028 |
4.73% 902/1067 |
10.05% 593/1164 |
4.93% 824/1184 |
| 2019 | 33.11% 438/1092 |
28.26% 320/754 |
0.19% 189/804 |
-2.94% 718/850 |
6.72% 560/918 |
| 2018 | -19.94% 184/834 |
- - |
- - |
- - |
-9.69% 159/691 |
| 2017 | 16.53% 235/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.22% 278/605 |
- - |
- - |
- - |
- - |
| 2015 | -2.82% 270/575 |
- - |
- - |
- - |
- - |
| 2014 | 88.18% 4/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 汇添富中证金融地产ETF VS. 长安沪深300非周期A(740101) |